Literature DB >> 12614988

Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization.

Soraya Andrade-Baiocchi1, Maria Cristina B Tognim, Otavio C G Baiocchi, Helio S Sader.   

Abstract

We report a case of infective endocarditis due to vancomycin-intermediate Staphylococcus aureus (VISA) that did not respond to high doses of vancomycin. Initial vancomycin MIC of the last isolate recovered from blood was 8 micro g/mL, but could be induced up to 32 micro g/mL by consecutive growing with vancomycin. Clinical response was only accomplished when linezolid was included in therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12614988     DOI: 10.1016/s0732-8893(02)00511-4

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  5 in total

1.  Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus.

Authors:  Mandy Wootton; T R Walsh; A P MacGowan
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 2.  Infective endocarditis treated with linezolid: case report and literature review.

Authors:  E E Hill; P Herijgers; M-C Herregods; W E Peetermans
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-03       Impact factor: 3.267

3.  First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia.

Authors:  S Al-Obeid; Q Haddad; A Cherkaoui; J Schrenzel; P François
Journal:  J Clin Microbiol       Date:  2010-04-14       Impact factor: 5.948

Review 4.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

5.  Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.

Authors:  Aref Shariati; Masoud Dadashi; Majid Taati Moghadam; Alex van Belkum; Somayeh Yaslianifard; Davood Darban-Sarokhalil
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.